福岛年轻人群中BRAFV600E突变甲状腺癌的临床病理结果
分析2013至2016年在福岛医科大学医院手术的138例(男52例、女86例)0至18岁甲状腺超声筛查发现的甲状腺癌病例,136例(98.6%)为甲状腺乳头状癌(PTC)。BRAFV600E突变检出96例(69.6%),致癌性重排检出23例(16.7%)。BRAFV600E突变组肿瘤更小但中央区淋巴结转移率更高。
要点
- BRAFV600E突变在福岛年轻PTC中检出率为69.6%(96/138)。
- BRAFV600E突变组肿瘤大小12.8±6.8 mm,小于野生型组的20.9±10.5 mm。
- BRAFV600E突变组淋巴结转移83例(86.5%),高于野生型组的26例(61.9%)。
核心结论
- BRAFV600E突变主要在福岛居民中检出,与切尔诺贝利后RET/PTC3重排为主的PTC不同。
- 在福岛年轻人群中,BRAFV600E突变PTC较野生型BRAF PTC更小,但中央区淋巴结转移率更高。
研究设计与样本
- 分析2013年至2016年在福岛医科大学医院手术的138例(男52例、女86例)甲状腺癌病例,这些病例来自福岛县0至18岁儿童甲状腺超声筛查。
- 术后病理诊断显示136例(98.6%)为甲状腺乳头状癌(PTC)。
- 采用直接DNA测序检测BRAFV600E突变,并检测致癌性重排。
主要发现
- BRAFV600E突变检出96例(69.6%)。
- 致癌性重排检出23例(16.7%),包括RET/PTC1 8例(5.8%)、ETV6(ex4)/NTRK3 6例(4.3%)、STRN/ALK 2例(1.4%),以及RET/PTC3、AFAP1L2/RET、PPFIBP/RET、KIAA1217/RET、ΔRFP/RET、SQSTM1/NTRK3和TPR/NTRK1各1例。
- BRAFV600E突变组肿瘤大小为12.8±6.8 mm,野生型BRAF组为20.9±10.5 mm。
- BRAFV600E突变组淋巴结转移83例(86.5%),野生型BRAF组淋巴结转移26例(61.9%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyroid ultrasound screening for children aged 0 to 18 years was performed in Fukushima following the accident at the Fukushima Daiichi Nuclear Power Plant. As a result, many thyroid cancer cases were detected. To explore the carcinogenic mechanisms of these cancers, we analyzed their clinicopathological and genetic features. METHODS: We analyzed 138 cases (52 males and 86 females) who had undergone surgery between 2013 and 2016 at Fukushima Medical University Hospital. Postoperative pathological diagnosis revealed 136 (98.6%) cases of papillary thyroid cancer (PTC). RESULTS: The BRAFV600E mutation was detected using direct DNA sequencing in 96 (69.6%) of the thyroid cancer cases. In addition, oncogenic rearrangements were detected in 23 cases (16.7%). Regarding chromosomal rearrangements, 8 (5.8%) RET/PTC1, 6 (4.3%) ETV6(ex4)/NTRK3, 2 (1.4%) STRN/ALK, and 1 each of RET/PTC3, AFAP1L2/RET, PPFIBP/RET, KIAA1217/RET, ΔRFP/RET, SQSTM1/NTRK3 and TPR/NTRK1 were detected. Tumor size was smaller in the BRAFV600E mutation cases (12.8 ± 6.8 mm) than in wild-type BRAF cases (20.9 ± 10.5 mm). In the BRAFV600E mutation cases, 83 (86.5%) showed lymph node metastasis, whereas 26 (61.9%) of the wild-type BRAF cases showed lymph node metastasis. CONCLUSIONS: The BRAFV600E mutation was mainly detected in residents of Fukushima, which was different from post-Chernobyl PTC cases with RET/PTC3 rearrangement. PTC with the BRAFV600E mutation was smaller but was shown in the high rate of central cervical lymph node metastasis than the wild-type BRAF PTC in the young population of Fukushima.
引用
- Iwadate M, Mitsutake N, Matsuse M, et al. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima. J Clin Endocrinol Metab. 2020. PMID: 32827026. doi:10.1210/clinem/dgaa573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。